300601 康泰生物
已收盘 07-20 15:00:00
资讯
新帖
简况
7月17日康泰生物跌5.53%,疫苗ETF嘉实基金重仓该股
证券之星 · 07-17
7月17日康泰生物跌5.53%,疫苗ETF嘉实基金重仓该股
康泰生物:7月15日董事刘建凯减持股份合计4.1万股
证券之星 · 07-16
康泰生物:7月15日董事刘建凯减持股份合计4.1万股
康泰生物:7月14日董事刘建凯减持股份合计2.9万股
证券之星 · 07-15
康泰生物:7月14日董事刘建凯减持股份合计2.9万股
股市必读:康泰生物(300601)7月8日董秘有最新回复
证券之星 · 07-09
股市必读:康泰生物(300601)7月8日董秘有最新回复
康泰生物(300601)披露可转换公司债券2026年付息公告,7月8日股价下跌0.96%
证券之星 · 07-08
康泰生物(300601)披露可转换公司债券2026年付息公告,7月8日股价下跌0.96%
康泰生物:公司积极推动五联苗Ⅲ期临床试验进程
证券之星 · 07-08
康泰生物:公司积极推动五联苗Ⅲ期临床试验进程
康泰生物:公司获批上市的四价流感病毒裂解疫苗
证券之星 · 07-08
康泰生物:公司获批上市的四价流感病毒裂解疫苗
康泰生物:业绩滑坡与治理乱象交织,疫苗白马何以陷落?
新浪证券 · 07-03
康泰生物:业绩滑坡与治理乱象交织,疫苗白马何以陷落?
康泰生物(300601)披露2026年第二季度可转换公司债券转股情况公告,7月2日股价下跌1.76%
证券之星 · 07-02
康泰生物(300601)披露2026年第二季度可转换公司债券转股情况公告,7月2日股价下跌1.76%
康泰生物(300601)披露2026年债券跟踪评级报告,7月1日股价上涨5.29%
证券之星 · 07-01
康泰生物(300601)披露2026年债券跟踪评级报告,7月1日股价上涨5.29%
7月1日康泰生物涨5.29%,疫苗ETF嘉实基金重仓该股
证券之星 · 07-01
7月1日康泰生物涨5.29%,疫苗ETF嘉实基金重仓该股
6月29日康泰生物涨5.56%,疫苗ETF嘉实基金重仓该股
证券之星 · 06-29
6月29日康泰生物涨5.56%,疫苗ETF嘉实基金重仓该股
康泰生物涨5.56%,东海证券二个月前给出“买入”评级
证券之星 · 06-29
康泰生物涨5.56%,东海证券二个月前给出“买入”评级
每周股票复盘:康泰生物(300601)不修正转股价格
证券之星 · 06-21
每周股票复盘:康泰生物(300601)不修正转股价格
康泰生物(300601)披露公司及全资子公司提供担保进展公告,6月17日股价下跌0.52%
证券之星 · 06-17
康泰生物(300601)披露公司及全资子公司提供担保进展公告,6月17日股价下跌0.52%
康泰生物(300601)披露不向下修正“康泰转2”转股价格的公告,6月16日股价上涨0.35%
证券之星 · 06-16
康泰生物(300601)披露不向下修正“康泰转2”转股价格的公告,6月16日股价上涨0.35%
6月15日康泰生物现355.09万元大宗交易
证券之星 · 06-15
6月15日康泰生物现355.09万元大宗交易
康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间
智通财经 · 06-15
康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间
康泰生物(300601)披露控股股东部分股份质押公告,5月21日股价下跌2.75%
证券之星 · 05-21
康泰生物(300601)披露控股股东部分股份质押公告,5月21日股价下跌2.75%
康泰生物涨7.16%,东海证券一周前给出“买入”评级
证券之星 · 05-11
康泰生物涨7.16%,东海证券一周前给出“买入”评级
加载更多
公司概况
公司名称:
深圳康泰生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2017-02-07
主营业务:
深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。
发行价格:
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":12.43,"timestamp":1784530980000,"preClose":12.14,"halted":0,"volume":19941843,"delay":0,"changeRate":0.0239,"floatShares":900000000,"shares":1117000000,"eps":0.0728,"marketStatus":"已收盘","change":0.29,"latestTime":"07-20 15:00:00","open":12.1,"high":12.48,"low":12.04,"amount":246000000,"amplitude":0.0362,"askPrice":12.43,"askSize":640,"bidPrice":12.42,"bidSize":800,"shortable":0,"etf":0,"ttmEps":0.0728,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784597400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.14,"symbolType":"stock","openAndCloseTimeList":[[1784511000000,1784518200000],[1784523600000,1784530800000]],"highLimit":13.35,"lowLimit":10.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116930267,"isCdr":false,"pbRate":1.48,"roa":"--","peRate":170.741758,"roe":"0.35%","epsLYR":0.06,"committee":-0.275109,"marketValue":13883000000,"turnoverRate":0.0221,"status":0,"floatMarketCap":11192000000},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2652060334","title":"7月17日康泰生物跌5.53%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652060334","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652060334?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:54","pubTimestamp":1784278461,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日康泰生物跌5.53%,收盘报12.14元,换手率2.9%,成交量26.14万手,成交额3.24亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元,最新净值0.6651,较上一交易日下跌0.24%,近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["562860","BK0239","BK0201","BK0046","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651421674","title":"康泰生物:7月15日董事刘建凯减持股份合计4.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651421674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651421674?lang=zh_cn&edition=full","pubTime":"2026-07-16 21:01","pubTimestamp":1784206911,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月16日市场公开信息、上市公司公告及交易所披露数据整理,康泰生物最新董监高及相关人员股份变动情况:2026年7月15日公司董事,高管刘建凯共减持公司股份4.1万股,占公司总股本为0.0037%。康泰生物近半年内的董监高及核心技术人员增减持详情如下:康泰生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出147.31万,融资余额减少;融券净流出1900.0,融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600038512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651654794","title":"康泰生物:7月14日董事刘建凯减持股份合计2.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651654794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651654794?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:01","pubTimestamp":1784120501,"startTime":"0","endTime":"0","summary":"证券之星消息,根据7月15日市场公开信息、上市公司公告及交易所披露数据整理,康泰生物最新董监高及相关人员股份变动情况:2026年7月14日公司董事,高管刘建凯共减持公司股份2.9万股,占公司总股本为0.0026%。康泰生物近半年内的董监高及核心技术人员增减持详情如下:康泰生物的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出662.62万,融资余额减少;融券净流出3.63万,融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500043222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650723918","title":"股市必读:康泰生物(300601)7月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2650723918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650723918?lang=zh_cn&edition=full","pubTime":"2026-07-09 02:22","pubTimestamp":1783534932,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,康泰生物报收于11.34元,下跌0.96%,换手率1.4%,成交量12.58万手,成交额1.43亿元。公司公告汇总:康泰生物发布“康泰转2”可转换公司债券2026年付息公告,第五年票面利率1.80%,每10张派息18.00元(含税),债权登记日为2026年7月14日,付息日为2026年7月15日。付息对象为中国结算深圳分公司登记在册的全体“康泰转2”持有人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900001793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649994252","title":"康泰生物(300601)披露可转换公司债券2026年付息公告,7月8日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649994252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649994252?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:36","pubTimestamp":1783521381,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,康泰生物报收于11.34元,较前一交易日下跌0.96%,最新总市值为126.66亿元。近日,深圳康泰生物制品股份有限公司发布关于“康泰转2”可转换公司债券2026年付息公告。本次付息为第五年付息,计息期间为2025年7月15日至2026年7月14日,票面利率为1.80%。债权登记日为2026年7月14日,付息日为2026年7月15日。付息对象为中国结算深圳分公司登记在册的全体“康泰转2”持有人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800043025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300601","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649096967","title":"康泰生物:公司积极推动五联苗Ⅲ期临床试验进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2649096967","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649096967?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:21","pubTimestamp":1783506081,"startTime":"0","endTime":"0","summary":"证券之星消息,康泰生物(300601)07月08日在投资者关系平台上答复投资者关心的问题。投资者提问:贵公司5联苗3期进展如何?康泰生物回复:您好,公司积极推动五联苗Ⅲ期临床试验进程,目前已完成受试者入组,后续如产品研发及注册进展达到信息披露标准的,公司将会根据相关法律法规的规定履行信息披露义务。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800035550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0239","300601","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679639","title":"康泰生物:公司获批上市的四价流感病毒裂解疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679639","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649679639?lang=zh_cn&edition=full","pubTime":"2026-07-08 18:12","pubTimestamp":1783505528,"startTime":"0","endTime":"0","summary":"投资者提问:公司已经有了四价流感病毒疫苗,为何还要投钱研发三价流感病毒裂解疫苗?","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800033761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0201","159646","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648165273","title":"康泰生物:业绩滑坡与治理乱象交织,疫苗白马何以陷落?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648165273","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648165273?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:54","pubTimestamp":1783068840,"startTime":"0","endTime":"0","summary":"曾经的疫苗行业白马股康泰生物,如今正面临业绩失速与治理争议的双重夹击。2025年年报与2026年一季报相继披露后,市场看到的不仅是一份利润暴跌的答卷,更是一系列令投资者不安的资本运作与治理乱象。从核心产品失灵到实控人离婚减持,再到“零元受让”关联公司,康泰生物的风险链条正逐步释放,其背后的深层问题值得警惕。 康泰生物2025年的业绩表现堪称惨淡。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-03/doc-inifpkaw2429174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","300601","BK0201","BK0239","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648848689","title":"康泰生物(300601)披露2026年第二季度可转换公司债券转股情况公告,7月2日股价下跌1.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648848689","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648848689?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:05","pubTimestamp":1783004721,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘,康泰生物报收于11.73元,较前一交易日下跌1.76%,最新总市值为131.02亿元。该股当日开盘11.89元,最高12.26元,最低11.71元,成交额达2.13亿元,换手率为2.0%。近日,深圳康泰生物制品股份有限公司发布2026年第二季度可转换公司债券转股情况公告。“康泰转2”转股期限为2022年1月21日至2027年7月14日,当前转股价格为15.69元/股。2026年第二季度,共有81张“康泰转2”完成转股,合计转为512股公司股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648541511","title":"康泰生物(300601)披露2026年债券跟踪评级报告,7月1日股价上涨5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648541511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648541511?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:48","pubTimestamp":1782899294,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,康泰生物报收于11.94元,较前一交易日上涨5.29%,最新总市值为133.36亿元。该股当日开盘11.32元,最高11.99元,最低11.14元,成交额达2.81亿元,换手率为2.68%。近日,深圳康泰生物制品股份有限公司披露《相关债券2026年跟踪评级报告》。中证鹏元维持公司主体信用等级AA,评级展望为稳定,同时维持“康泰转2”信用等级AA。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648425516","title":"7月1日康泰生物涨5.29%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648425516","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648425516?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:53","pubTimestamp":1782895993,"startTime":"0","endTime":"0","summary":"证券之星消息,7月1日康泰生物涨5.29%,收盘报11.94元,换手率2.68%,成交量24.1万手,成交额2.81亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元,最新净值0.6219,较上一交易日下跌0.14%,近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239","562860"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322147","title":"6月29日康泰生物涨5.56%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647322147?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:51","pubTimestamp":1782723114,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日康泰生物涨5.56%创60日新低,收盘报11.58元,换手率2.6%,成交量23.39万手,成交额2.67亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元,最新净值0.5806,较上一交易日下跌4.27%,近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0046","562860","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647732291","title":"康泰生物涨5.56%,东海证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647732291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647732291?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:51","pubTimestamp":1782723104,"startTime":"0","endTime":"0","summary":"今日康泰生物涨5.56%,收盘报11.58元。2026年4月28日,东海证券研究员杜永宏,付婷发布了对康泰生物的研报《公司简评报告:收入端平稳,产品管线布局丰富》,该研报对康泰生物给出“买入”评级。公司持续推进创新研发,新产品陆续获批上市,维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为国投证券的冯俊曦、李奔。康泰生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645233096","title":"每周股票复盘:康泰生物(300601)不修正转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2645233096","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645233096?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:27","pubTimestamp":1781983630,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,康泰生物报收于11.52元,较上周的11.75元下跌1.96%。本周,康泰生物6月18日盘中最高价报11.77元。本次交易不涉及现金对价支付,由康泰生物承担后续出资义务。自2026年5月26日至2026年6月15日,康泰生物股票在连续三十个交易日中已有十五个交易日的收盘价低于当期转股价格的85%,触发“康泰转2”转股价格向下修正条款。公司于2026年6月15日召开董事会审议通过不向下修正转股价格的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644742640","title":"康泰生物(300601)披露公司及全资子公司提供担保进展公告,6月17日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644742640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644742640?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:42","pubTimestamp":1781707338,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,康泰生物报收于11.54元,较前一交易日下跌0.52%,最新总市值为128.89亿元。近日,康泰生物发布《关于公司及全资子公司提供担保进展的公告》。公告显示,深圳康泰生物制品股份有限公司及全资子公司北京民海生物科技有限公司于2026年4月21日经董事会审议通过,互为对方金融机构融资提供连带责任保证担保。截至公告日,公司及子公司对外担保本金合计5,716.62万元,占2025年度经审计净资产的0.59%,无逾期担保及其他对外担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753875","title":"康泰生物(300601)披露不向下修正“康泰转2”转股价格的公告,6月16日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643753875?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:44","pubTimestamp":1781603055,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,康泰生物报收于11.6元,较前一交易日上涨0.35%,最新总市值为129.56亿元。公告显示,自2026年5月26日至2026年6月15日,公司股票在连续三十个交易日中已有十五个交易日的收盘价低于当期转股价格的85%,触发“康泰转2”转股价格向下修正条款。公司于2026年6月15日召开第八届董事会第十次会议,审议通过不向下修正“康泰转2”转股价格的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600032017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643743712","title":"6月15日康泰生物现355.09万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2643743712","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643743712?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:41","pubTimestamp":1781516467,"startTime":"0","endTime":"0","summary":"证券之星消息,6月15日康泰生物发生大宗交易,交易数据如下:大宗交易成交价格11.75元,相对当日收盘价溢价1.64%,成交30.22万股,成交金额355.09万元,买方营业部为机构专用,卖方营业部为机构专用。近三个月该股共发生18笔大宗交易,合计成交13.39万手,溢价成交18笔。截至2026年6月15日收盘,康泰生物报收于11.56元,下跌1.62%,换手率1.7%,成交量15.28万手,成交额1.77亿元。本文数据来源于深圳证券交易所大宗交易信息披露,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500022467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643271761","title":"康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2643271761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643271761?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:28","pubTimestamp":1781515732,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康泰生物(300601.SZ)发布公告,公司拟以零元受让北京琨远生物科技有限公司(简称“北京琨远”)原股东持有的已认缴但尚未实缴的51%股权(对应认缴注册资本5100万元,实缴注册资本0元),且实现并表。鉴于标的公司于2026年3月6日注册成立,存续时间较短,且交易对手方所转让股权对应的注册资本尚未实缴,各方协商确定此次交易作价零元。此次收购旨在拓宽公司业务发展空间,实现业务多元化发展,增强公司的持续经营能力,强化公司的核心竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康泰生物(300601.SZ)拟零元受让北京琨远51%股权 拓宽公司业务发展空间","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","300601","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637057381","title":"康泰生物(300601)披露控股股东部分股份质押公告,5月21日股价下跌2.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637057381","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637057381?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:49","pubTimestamp":1779356986,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘,康泰生物报收于13.44元,较前一交易日下跌2.75%,最新总市值为150.12亿元。该股当日开盘13.8元,最高14.0元,最低13.4元,成交额达1.75亿元,换手率为1.41%。公司于近日披露《关于控股股东、实际控制人部分股份质押的公告》。质押起始日为2026年5月19日,到期日为2027年5月18日。截至公告日,杜伟民累计质押股份78,650,000股,占其所持股份比例27.62%,占公司总股本比例7.04%。公司表示其质押股份不存在平仓风险,不会导致实际控制权变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100033381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409450","title":"康泰生物涨7.16%,东海证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409450?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:37","pubTimestamp":1778488663,"startTime":"0","endTime":"0","summary":"今日康泰生物涨7.16%,收盘报15.57元。2026年4月28日,东海证券研究员杜永宏,付婷发布了对康泰生物的研报《公司简评报告:收入端平稳,产品管线布局丰富》,该研报对康泰生物给出“买入”评级。公司持续推进创新研发,新产品陆续获批上市,维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为10.47%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为国投证券的冯俊曦、李奔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784589718356,"stockEarnings":[{"period":"1week","weight":0.0463},{"period":"1month","weight":0.079},{"period":"3month","weight":-0.0999},{"period":"6month","weight":-0.1982},{"period":"1year","weight":-0.237},{"period":"ytd","weight":-0.1559}],"compareEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.0719},{"period":"3month","weight":-0.0707},{"period":"6month","weight":-0.0779},{"period":"1year","weight":0.0741},{"period":"ytd","weight":-0.0435}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"61919人(较上一季度增加1.07%)","perCapita":"14541股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111693万元","survey":" 深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}